{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T04:53:33Z","timestamp":1794027213517,"version":"4.8.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100013281","name":"Joint Programming Initiative on Antimicrobial Resistance","doi-asserted-by":"publisher","award":["MAGITICS_JPIAMR_2019_P011"],"award-info":[{"award-number":["MAGITICS_JPIAMR_2019_P011"]}],"id":[{"id":"10.13039\/100013281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013281","name":"Joint Programming Initiative on Antimicrobial Resistance","doi-asserted-by":"publisher","award":["MAGITICS_JPIAMR_2019_P011"],"award-info":[{"award-number":["MAGITICS_JPIAMR_2019_P011"]}],"id":[{"id":"10.13039\/100013281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Microbiol"],"DOI":"10.1186\/s12866-025-04517-z","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T03:23:24Z","timestamp":1765250604000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Deciphering the emergence of mutations in Pseudomonas aeruginosa after ceftolozane\/tazobactam treatment and evaluating therapeutic alternatives"],"prefix":"10.1186","volume":"26","author":[{"given":"L\u00e9a","family":"Bientz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Boijout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raoudha","family":"Grami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulysse","family":"Guyet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marin","family":"Lahouati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissande","family":"Hertzmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Toirot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Aillerie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Coulange-Mayonnove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Groppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macha","family":"Nikolski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"B\u00e9b\u00e9ar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"4517_CR1","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2165\/00003495-200767030-00003","volume":"67","author":"JA Driscoll","year":"2007","unstructured":"Driscoll JA, Brody SL, Kollef MH. The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs. 2007;67:351\u201368. https:\/\/doi.org\/10.2165\/00003495-200767030-00003.","journal-title":"Drugs"},{"key":"4517_CR2","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1128\/CMR.00040-09","volume":"22","author":"PD Lister","year":"2009","unstructured":"Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev. 2009;22:582\u2013610. https:\/\/doi.org\/10.1128\/CMR.00040-09.","journal-title":"Clin Microbiol Rev"},{"key":"4517_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.00685","author":"C L\u00f3pez-Causap\u00e9","year":"2018","unstructured":"L\u00f3pez-Causap\u00e9 C, Cabot G, del Barrio-Tofi\u00f1o E, Oliver A. The versatile mutational resistome of Pseudomonas aeruginosa. Front Microbiol. 2018. https:\/\/doi.org\/10.3389\/fmicb.2018.00685.","journal-title":"Front Microbiol"},{"key":"4517_CR4","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/j.1469-0691.2009.03116.x","volume":"16","author":"V Miriagou","year":"2010","unstructured":"Miriagou V, Cornaglia G, Edelstein M, Galani I, Giske CG, Gniadkowski M, et al. Acquired carbapenemases in gram-negative bacterial pathogens: detection and surveillance issues. Clin Microbiol Infect. 2010;16:112\u201322. https:\/\/doi.org\/10.1111\/j.1469-0691.2009.03116.x.","journal-title":"Clin Microbiol Infect"},{"key":"4517_CR5","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1128\/AAC.03954-14","volume":"59","author":"VN Kos","year":"2015","unstructured":"Kos VN, D\u00e9raspe M, McLaughlin RE, Whiteaker JD, Roy PH, Alm RA, et al. The resistome of Pseudomonas aeruginosa in relationship to phenotypic susceptibility. Antimicrob Agents Chemother. 2015;59:427\u201336. https:\/\/doi.org\/10.1128\/AAC.03954-14.","journal-title":"Antimicrob Agents Chemother"},{"key":"4517_CR6","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02125-17","author":"M Castanheira","year":"2017","unstructured":"Castanheira M, Duncan LR, Mendes RE, Sader HS, Shortridge D. Activity of Ceftolozane-Tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae isolates collected from respiratory tract specimens of hospitalized patients in the united States during 2013 to 2015. Antimicrob Agents Chemother. 2017. https:\/\/doi.org\/10.1128\/AAC.02125-17. :AAC.02125-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"4517_CR7","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/jac\/dkx009","volume":"72","author":"MA Pfaller","year":"2017","unstructured":"Pfaller MA, Bassetti M, Duncan LR, Castanheira M. Ceftolozane\/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012\u201315). J Antimicrob Chemother. 2017;72:1386\u201395. https:\/\/doi.org\/10.1093\/jac\/dkx009.","journal-title":"J Antimicrob Chemother"},{"key":"4517_CR8","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jinf.2014.04.004","volume":"69","author":"HS Sader","year":"2014","unstructured":"Sader HS, Farrell DJ, Flamm RK, Jones RN. Ceftolozane\/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012). J Infect. 2014;69:266\u201377. https:\/\/doi.org\/10.1016\/j.jinf.2014.04.004.","journal-title":"J Infect"},{"key":"4517_CR9","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.ijantimicag.2014.01.032","volume":"43","author":"DJ Farrell","year":"2014","unstructured":"Farrell DJ, Sader HS, Flamm RK, Jones RN. Ceftolozane\/tazobactam activity tested against gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). Int J Antimicrob Agents. 2014;43:533\u20139. https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.01.032.","journal-title":"Int J Antimicrob Agents"},{"key":"4517_CR10","doi-asserted-by":"publisher","first-page":"6248","DOI":"10.1128\/AAC.00825-15","volume":"59","author":"M Berrazeg","year":"2015","unstructured":"Berrazeg M, Jeannot K, Engu\u00e9n\u00e9 VYN, Broutin I, Loeffert S, Fournier D, et al. Mutations in \u03b2-lactamase AmpC increase resistance of Pseudomonas aeruginosa isolates to antipseudomonal cephalosporins. Antimicrob Agents Chemother. 2015;59:6248\u201355. https:\/\/doi.org\/10.1128\/AAC.00825-15.","journal-title":"Antimicrob Agents Chemother"},{"key":"4517_CR11","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1093\/jac\/dkx424","volume":"73","author":"PA Fraile-Ribot","year":"2018","unstructured":"Fraile-Ribot PA, Cabot G, Mulet X, Peria\u00f1ez L, Mart\u00edn-Pena ML, Juan C, et al. Mechanisms leading to in vivo ceftolozane\/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa. J Antimicrob Chemother. 2018;73:658\u201363. https:\/\/doi.org\/10.1093\/jac\/dkx424.","journal-title":"J Antimicrob Chemother"},{"key":"4517_CR12","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1128\/AAC.02462-13","volume":"58","author":"G Cabot","year":"2014","unstructured":"Cabot G, Bruchmann S, Mulet X, Zamorano L, Moy\u00e0 B, Juan C, et al. Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC. Antimicrob Agents Chemother. 2014;58:3091\u20139. https:\/\/doi.org\/10.1128\/AAC.02462-13.","journal-title":"Antimicrob Agents Chemother"},{"key":"4517_CR13","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1093\/cid\/cix182","volume":"65","author":"G Haidar","year":"2017","unstructured":"Haidar G, Philips NJ, Shields RK, Snyder D, Cheng S, Potoski BA, et al. Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance. Clin Infect Dis. 2017;65:110\u201320. https:\/\/doi.org\/10.1093\/cid\/cix182.","journal-title":"Clin Infect Dis"},{"key":"4517_CR14","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1089\/cmb.2012.0021","volume":"19","author":"A Bankevich","year":"2012","unstructured":"Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol. 2012;19:455\u201377. https:\/\/doi.org\/10.1089\/cmb.2012.0021.","journal-title":"J Comput Biol"},{"key":"4517_CR15","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/bioinformatics\/btt086","volume":"29","author":"A Gurevich","year":"2013","unstructured":"Gurevich A, Saveliev V, Vyahhi N, Tesler G. QUAST: quality assessment tool for genome assemblies. Bioinformatics. 2013;29:1072\u20135. https:\/\/doi.org\/10.1093\/bioinformatics\/btt086.","journal-title":"Bioinformatics"},{"key":"4517_CR16","doi-asserted-by":"publisher","first-page":"3210","DOI":"10.1093\/bioinformatics\/btv351","volume":"31","author":"FA Sim\u00e3o","year":"2015","unstructured":"Sim\u00e3o FA, Waterhouse RM, Ioannidis P, Kriventseva EV, Zdobnov EM. Busco: assessing genome assembly and annotation completeness with single-copy orthologs. Bioinformatics. 2015;31:3210\u20132. https:\/\/doi.org\/10.1093\/bioinformatics\/btv351.","journal-title":"Bioinformatics"},{"key":"4517_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-022-02823-7","volume":"23","author":"M Alonge","year":"2022","unstructured":"Alonge M, Lebeigle L, Kirsche M, Jenike K, Ou S, Aganezov S, et al. Automated assembly scaffolding using ragtag elevates a new tomato system for high-throughput genome editing. Genome Biol. 2022;23:258. https:\/\/doi.org\/10.1186\/s13059-022-02823-7.","journal-title":"Genome Biol"},{"issue":"44","key":"4517_CR18","doi-asserted-by":"publisher","DOI":"10.21105\/joss.01762","volume":"4","author":"LS Katz","year":"2019","unstructured":"Katz LS, Griswold T, Morrison SS, Caravas JA, Zhang S, Bakker HC, et al. Mashtree: a rapid comparison of whole genome sequence files. J Open Source Softw. 2019;4(44):1762. https:\/\/doi.org\/10.21105\/joss.01762.","journal-title":"J Open Source Softw"},{"key":"4517_CR19","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1093\/bioinformatics\/btu153","volume":"30","author":"T Seemann","year":"2014","unstructured":"Seemann T. Prokka: rapid prokaryotic genome annotation. Bioinformatics. 2014;30:2068\u20139. https:\/\/doi.org\/10.1093\/bioinformatics\/btu153.","journal-title":"Bioinformatics"},{"issue":"1","key":"4517_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-91456-0","volume":"11","author":"M Feldgarden","year":"2021","unstructured":"Feldgarden M, Brover V, Gonzalez-Escalona N, Frye JG, Haendiges J, Haft DH, et al. AMRFinderPlus and the reference gene catalog facilitate examination of the genomic links among antimicrobial resistance, stress response, and virulence. Sci Rep. 2021;11(1):12728. https:\/\/doi.org\/10.1038\/s41598-021-91456-0.","journal-title":"Sci Rep"},{"key":"4517_CR21","doi-asserted-by":"publisher","DOI":"10.1099\/mgen.0.000166","volume":"4","author":"M Silva","year":"2018","unstructured":"Silva M, Machado MP, Silva DN, Rossi M, Moran-Gilad J, Santos S, et al. ChewBBACA: a complete suite for gene-by-gene schema creation and strain identification. Microb Genom. 2018;4:e000166. https:\/\/doi.org\/10.1099\/mgen.0.000166.","journal-title":"Microb Genom"},{"key":"4517_CR22","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01987-20","volume":"59","author":"H T\u00f6nnies","year":"2021","unstructured":"T\u00f6nnies H, Prior K, Harmsen D, Mellmann A. Establishment and evaluation of a core genome multilocus sequence typing scheme for whole-genome sequence-based typing of Pseudomonas aeruginosa. J Clin Microbiol. 2021;59:e01987\u201320. https:\/\/doi.org\/10.1128\/JCM.01987-20.","journal-title":"J Clin Microbiol"},{"key":"4517_CR23","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1093\/bioinformatics\/btp033","volume":"25","author":"AM Waterhouse","year":"2009","unstructured":"Waterhouse AM, Procter JB, Martin DMA, Clamp M, Barton GJ. Jalview version 2\u2014a multiple sequence alignment editor and analysis workbench. Bioinformatics. 2009;25:1189\u201391. https:\/\/doi.org\/10.1093\/bioinformatics\/btp033.","journal-title":"Bioinformatics"},{"key":"4517_CR24","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.03588-22","volume":"11","author":"M Biggel","year":"2023","unstructured":"Biggel M, Johler S, Roloff T, Tschudin-Sutter S, Bassetti S, Siegemund M, et al. PorinPredict: in silico identification of OprD loss from WGS data for improved genotype-phenotype predictions of P. aeruginosa carbapenem resistance. Microbiol Spectr. 2023;11:e03588\u201322. https:\/\/doi.org\/10.1128\/spectrum.03588-22.","journal-title":"Microbiol Spectr"},{"key":"4517_CR25","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"A-P Magiorakos","year":"2012","unstructured":"Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268\u201381. https:\/\/doi.org\/10.1111\/j.1469-0691.2011.03570.x.","journal-title":"Clin Microbiol Infect"},{"key":"4517_CR26","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00084-21","volume":"65","author":"AM Rubio","year":"2021","unstructured":"Rubio AM, Kline EG, Jones CE, Chen L, Kreiswirth BN, Nguyen MH, et al. In vitro susceptibility of multidrug-resistant Pseudomonas aeruginosa following treatment-emergent resistance to ceftolozane-tazobactam. Antimicrob Agents Chemother. 2021;65:e00084\u201321. https:\/\/doi.org\/10.1128\/AAC.00084-21.","journal-title":"Antimicrob Agents Chemother"},{"key":"4517_CR27","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1007\/s10096-018-3361-0","volume":"37","author":"M D\u00edaz-Ca\u00f1estro","year":"2018","unstructured":"D\u00edaz-Ca\u00f1estro M, Peria\u00f1ez L, Mulet X, Martin-Pena ML, Fraile-Ribot PA, Ayestar\u00e1n I, et al. Ceftolozane\/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands. Eur J Clin Microbiol Infect Dis. 2018;37:2191\u2013200. https:\/\/doi.org\/10.1007\/s10096-018-3361-0.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"4517_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106196","volume":"56","author":"E Del Barrio-Tofi\u00f1o","year":"2020","unstructured":"Del Barrio-Tofi\u00f1o E, L\u00f3pez-Causap\u00e9 C, Oliver A. Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired \u03b2-lactamases: 2020 update. Int J Antimicrob Agents. 2020;56:106196. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106196.","journal-title":"Int J Antimicrob Agents"},{"key":"4517_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1117017","volume":"14","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Chen D, Ji B, Zhang X, Anbo M, Jelsbak L. Whole-genome sequencing reveals high-risk clones of Pseudomonas aeruginosa in Guangdong, China. Front Microbiol. 2023;14:1117017. https:\/\/doi.org\/10.3389\/fmicb.2023.1117017.","journal-title":"Front Microbiol"},{"key":"4517_CR30","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01841-19","author":"AR Mack","year":"2020","unstructured":"Mack AR, Barnes MD, Taracila MA, Hujer AM, Hujer KM, Cabot G, et al. A standard numbering scheme for class C \u03b2-lactamases. Antimicrob Agents Chemother. 2020. https:\/\/doi.org\/10.1128\/aac.01841-19.","journal-title":"Antimicrob Agents Chemother"},{"key":"4517_CR31","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02067-21","volume":"66","author":"A Ruedas-L\u00f3pez","year":"2022","unstructured":"Ruedas-L\u00f3pez A, Alonso-Garc\u00eda I, Lasarte-Monterrubio C, Guijarro-S\u00e1nchez P, Gato E, V\u00e1zquez-Ucha JC, et al. Selection of AmpC \u03b2-lactamase variants and Metallo-\u03b2-lactamases leading to Ceftolozane\/Tazobactam and Ceftazidime\/Avibactam resistance during treatment of MDR\/XDR Pseudomonas aeruginosa infections. Antimicrob Agents Chemother. 2022;66:e02067\u201321. https:\/\/doi.org\/10.1128\/aac.02067-21.","journal-title":"Antimicrob Agents Chemother"},{"key":"4517_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.943346","volume":"12","author":"KM Hall","year":"2022","unstructured":"Hall KM, Pursell ZF, Morici LA. The role of the Pseudomonas aeruginosa hypermutator phenotype on the shift from acute to chronic virulence during respiratory infection. Front Cell Infect Microbiol. 2022;12:943346. https:\/\/doi.org\/10.3389\/fcimb.2022.943346.","journal-title":"Front Cell Infect Microbiol"},{"key":"4517_CR33","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01298-23","volume":"68","author":"A Ghassani","year":"2024","unstructured":"Ghassani A, Triponney P, Bour M, Pl\u00e9siat P, Jeannot K. Mutations in genes lpxL1, bamA, and PmrB impair the susceptibility of cystic fibrosis strains of Pseudomonas aeruginosa to murepavadin. Antimicrob Agents Chemother. 2024;68:e01298\u201323. https:\/\/doi.org\/10.1128\/aac.01298-23.","journal-title":"Antimicrob Agents Chemother"},{"key":"4517_CR34","doi-asserted-by":"publisher","first-page":"e02538","DOI":"10.1128\/AAC.02538-18","volume":"63","author":"VE Rees","year":"2019","unstructured":"Rees VE, Deveson Lucas DS, L\u00f3pez-Causap\u00e9 C, Huang Y, Kotsimbos T, Bulitta JB, et al. Characterization of hypermutator Pseudomonas aeruginosa isolates from patients with cystic fibrosis in Australia. Antimicrob Agents Chemother. 2019;63:e02538\u201318. https:\/\/doi.org\/10.1128\/AAC.02538-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"4517_CR35","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00894-20","author":"CL Slater","year":"2020","unstructured":"Slater CL, Winogrodzki J, Fraile-Ribot PA, Oliver A, Khajehpour M, Mark BL. Adding insult to injury: mechanistic basis for how AmpC mutations allow Pseudomonas aeruginosa to accelerate cephalosporin hydrolysis and evade avibactam. Antimicrob Agents Chemother. 2020. https:\/\/doi.org\/10.1128\/aac.00894-20.","journal-title":"Antimicrob Agents Chemother"},{"key":"4517_CR36","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01117-20","volume":"65","author":"D Fournier","year":"2021","unstructured":"Fournier D, Carri\u00e8re R, Bour M, Grisot E, Triponney P, Muller C, et al. Mechanisms of resistance to Ceftolozane\/Tazobactam in Pseudomonas aeruginosa: results of the GERPA multicenter study. Antimicrob Agents Chemother. 2021;65:e01117\u201320. https:\/\/doi.org\/10.1128\/AAC.01117-20.","journal-title":"Antimicrob Agents Chemother"},{"key":"4517_CR37","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1093\/jac\/dkad172","volume":"78","author":"MA Gomis-Font","year":"2023","unstructured":"Gomis-Font MA, Sastre-Femenia M\u00c0, Taltavull B, Cabot G, Oliver A. In vitro dynamics and mechanisms of Cefiderocol resistance development in wild-type, mutator and XDR Pseudomonas aeruginosa. J Antimicrob Chemother. 2023;78:1785\u201394. https:\/\/doi.org\/10.1093\/jac\/dkad172.","journal-title":"J Antimicrob Chemother"}],"container-title":["BMC Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-025-04517-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12866-025-04517-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-025-04517-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T04:55:26Z","timestamp":1768366526000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12866-025-04517-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4517"],"URL":"https:\/\/doi.org\/10.1186\/s12866-025-04517-z","relation":{},"ISSN":["1471-2180"],"issn-type":[{"value":"1471-2180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"assertion":[{"value":"13 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our study followed the MR-004 reference methodology, which governs the processing of retrospective and prospective personal data for health studies and evaluations in France. It was approved by the Data Protection Officer, and patients were informed about data collection in compliance with the EU General Data Protection Regulation. According to MR-004 and French legislation, written patient consent is no longer required before using their data. Patients did not oppose the use of their data for research purposes. Ethics approval is unnecessary according to national French regulations, MR-004 (\n                      \n                      ).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}